Company profile
aTYR PHARMA INC
NASDAQ:ATYRBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| EFZOFITIMOD | phase3 | — | 4 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (9)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05415137 | phase3 | completed | 2022-09-15 | 2025-06-25 | aTyr Pharma, Inc. | Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis |
| NCT02603562 | phase1_2 | completed | 2016-03-30 | 2016-12-12 | aTyr Pharma, Inc. | Evaluate Safety and Biological Activity of ATYR1940 in Participants With Early Onset Facioscapulohumeral Muscular Dystrophy |
| NCT02579239 | phase1_2 | completed | 2015-11-30 | 2016-10-05 | aTyr Pharma, Inc. | Evaluate Safety and Biological Activity of ATYR1940 in Participants With Limb Girdle Muscular Dystrophy 2B (LGMD2B) and Facioscapulohumeral Muscular Dystrophy (FSHD) |
| NCT02531217 | phase1_2 | completed | 2015-08-13 | 2016-05-26 | aTyr Pharma, Inc. | Safety, Tolerability, Pharmacokinetics (PK), and Activity of ATYR1940 in Participants With Muscular Dystrophy - Study Extension |
| NCT02239224 | phase1_2 | completed | 2014-09-04 | 2015-12-14 | aTyr Pharma, Inc. | Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATYR1940 in Adult Participants With Muscular Dystrophy |
FDA applications (0)
No records yet.